AMENDMENTS TO THE SPECIFICATION

Please replace the paragraph encompassing lines 7-24, at page 23 of the specification, with the following paragraph:

[^{3}H]PGD_2 binding assay described in Example 3 was carried out in the presence of various unlabeled prostanoids (products of Cayman), and the binding affinity of human CRTH2 to various prostanoids was evaluated. As a result, the order of the degree of the binding affinity of prostanoids to human CRTH2 was determined as follows: $PGD_2 \geq$ 13,14-dihydro-15-keto PGD_2 ~~13,14-dehydro-15-keto PGD_2~~ >> prostaglandin J_2 (PGJ_2) > 15-deoxydelta 12,14-$PGJ_2 \geq$ prostaglandin E_2 (PGE_2) = prostaglandin A_2 (PGA_2) >> thromboxane B_2 (TXB_2) (Fig. 3). For comparison, the order of the degree of the binding affinity of prostanoids to the DP receptor was determined as follows: $PGD_2 = PGJ_2 >> PGE_2 >$ 13,14-dihydro-15-keto PGD_2 ~~13,14-dehydro-15-keto PGD_2~~ > 15-deoxydelta 12,14-$PGJ_2 \geq TXB_2 \geq PGA_2$. These results show that the degree of the binding affinity of human CRTH2 to PGD_2 is equal to that of the binding affinity of the DP receptor to PGD_2, and that a great difference exists between human CRTH2 and the DP receptor in the degree of binding affinity to other prostanoids, such as 13,14-dehydro-15-keto PGD_2.